Stonebridge Ventures Sells Livesmed Shares to Global Fund...Managing Overhang Risk

Stonebridge Ventures announced on January 23 that it has sold a portion of its remaining unsold shares in portfolio company Livesmed, which were not subject to a lock-up, to a global long-term investment fund. This strategy goes beyond simply recovering the investment; it aims to alleviate supply-demand pressures in the market and enhance the shareholder structure.

Stonebridge Ventures stated that it transferred the unrestricted shares of Livesmed it held to a global long-only fund through a block deal (off-hours bulk trading). Long-only funds are institutional investor funds that focus on the intrinsic value and growth potential of companies, making medium- to long-term investments rather than seeking short-term price gains.

A representative from Stonebridge Ventures explained that the transaction was conducted by carefully selecting a global investor with strong confidence in Livesmed's technology and future growth prospects. In particular, the company expressed its intention to minimize the overhang issue (potential large-scale sell-off pressure) that often arises during the share sale process of major shareholders after a listing, and to increase the proportion of foreign investors to build a stable, long-term shareholder base.

Stonebridge Ventures also plans to actively consider additional block deals, rather than on-market sales, for shares that become available sequentially as lock-up periods expire and need to be disposed of due to reasons such as fund maturity. Through this, the company aims to control stock price volatility and maintain supply-demand stability. On the other hand, shares held by funds without maturity constraints will continue to be held in line with Livesmed’s medium- to long-term growth trajectory.

The market is interpreting this participation by global capital as an external validation of Livesmed's growth potential. Even if additional exit events occur in the future, overhang risk is expected to be systematically managed, which is projected to have a positive impact on Livesmed's share price and supply-demand stability.